<DOC>
	<DOCNO>NCT03073525</DOCNO>
	<brief_summary>This crossover study Vigil , Atezolizumab combination patient tumor harvest surgery successful manufacturing Vigil ineligible CL-PTL-119 ( VITAL study ) .</brief_summary>
	<brief_title>Trial Atezolizumab Vigil Advanced Gynecological Cancers ( A Companion Study CL-PTL-119 )</brief_title>
	<detailed_description>This randomize , open label intra-patient crossover study Vigil , checkpoint inhibitor Atezolizumab combination two agent , patient epithelial ovarian cancer , gynecological cancer ( i.e. , cervical , uterine ) . Eligible patient randomize receive two cycle Vigil alone two cycle atezolizumab alone , follow combination treatment two agents.This study intend companion study protocol CL-PTL-119 , A Randomized , Double Blind , Placebo Controlled Phase 3 trial Vigil Engineered Autologous Tumor Cell Immunotherapy Subjects Stage IIIb-IV Ovarian Cancer Clinical Complete Response follow Surgery Primary Chemotherapy , otherwise know VITAL study . Patients tumor harvest surgery Vigil successfully manufacture , ineligible randomization onto VITAL study , offer opportunity participate protocol .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Study Enrollment Subjects eligible registration trial meet follow inclusion criterion : 1 . Successful manufacturing least 4 vial Vigil . 2 . Failure meet eligibililty criterion Protocol CLPTL119 failure achieve complete clinical response follow primary debulking surgery standard paclitaxel/carboplatin therapy OR , histologic diagnosis another gynecologic malignancy ovarian cancer . 3 . ECOG performance status ( PS ) ≤ 1 4 . Estimated survival ≥ 6 month . 5 . Measureable evaluable disease . 6 . Adequate organ bone marrow function define : 1 . Absolute neutrophil count ( ANC ) ≥ 1.5 × 10e9/L ( 1500 per mm^3 ) 2 . Platelets &gt; 100 × 10e9/L ( 100,000 per mm^3 ) 3 . Hemoglobin ≥9.0 g/dL ( 5.59 mmol/L ) 4 . Creatinine clearance ( CrCL ) &gt; 50 mL/min CockcroftGault formula 24hour urine collection determination creatinine clearance : Females : CrCL ( mL/min ) = Weight ( kg ) × ( 140 Age ) × 0.85/72 × serum creatinine ( mg/dL ) 5 . Serum bilirubin ≤1.5 × upper limit normal ( ULN ) . This apply patient confirm Gilbert 's syndrome ( persistent recurrent hyperbilirubinemia predominantly unconjugated absence evidence hemolysis hepatic pathology ) allow consultation physician . 6 . AST ALT ≤2.5 × ULN patient liver metastasis 7 . AST ALT ≤5 × ULN patient liver metastasis 8 . TSH within institutional limit . If TSH great less institutional limit patient may participate T4 within normal limit ( WNL ) ; patient may stable dose replacement thyroid medication ; dose adjustment allow need 7 . Subject recover CTCAE Grade 1 good adverse event associate prior therapy surgery 8 . Preexisting motor sensory neurologic pathology symptom must recover CTCAE Grade ≤ 2 well 9 . Patients irreversible toxicity reasonably expect exacerbated IPs may include ( e.g. , hear loss ) consultation Principal Investigator 10 . Receipt last dose anticancer therapy ( chemotherapy , immunotherapy , endocrine therapy , target therapy , biologic therapy , tumor embolization , monoclonal antibody , investigational agent ) prior tissue procurement least 21 day prior first dose study drug ( least 21 day prior first dose study drug subject receive prior TKIs [ e.g. , erlotinib , gefitinib crizotinib ] within 6 week nitrosourea mitomycin C ) . ( If sufficient washout time occur due schedule PK property agent , long washout period may require . ) 11 . Subjects render surgically sterile result surgery ovarian cancer , must , negative urine serum pregnancy test . If urine test positive confirm negative , negative serum test require study entry . 12 . Ability understand willingness sign write inform protocol specific consent . 13 . Willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . Study Enrollment Subjects NOT eligible study registration enrollment meeting follow criterion : 1 . Have receive two additional chemotherapy regimens platinum resistant/refractory ovarian cancer , initial treatment paclitaxel/carboplatin , OR receive two additional chemotherapy regimens treatment another gynecologic malignancy 1 . Patients must fully recover chemotherapy associate toxicity prior start treatment protocol . 2 . Palliative radiotherapy permit provide : . More 3 week elapsed end radiotherapy first dose study therapy , AND ii . The lung radiation field , AND iii . The irradiated lesion ( ) use target lesion . 2 . Participation another clinical study investigational product within last 3 week prior study start . 3 . Patients autoimmune disease exclude enrollment exception patient hypothyroidism stable thyroxine replacement , patient T1DM stable insulin replacement . 4 . Receipt steroid therapy within 2 week first dose study therapy . 5 . Live vaccine use prevention infectious disease administer &lt; 30 day prior start study therapy . NOTE : Subjects , enrol , receive live vaccine study 5 month last dose atezolizumab . 6 . Postsurgery complication opinion treat investigator would interfere subject 's study participation make best interest subject participate . 7 . Mean QT interval correct heart rate ( QTc ) ≥470 m calculate 3 electrocardiogram ( ECGs ) use Frediricia 's Correction . 8 . Female subject pregnant , breastfeed reproductive potential employ effective method birth control define protocol . Effective contraception require woman receive atezolizumab 5 month last dose . 9 . Any condition , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stage IIIb</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Cervical Cancer</keyword>
	<keyword>Uterine Cancer</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>